NOVARTIS
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy
Phase 1
Completed
- Conditions
- First Posted Date
- 2007-04-24
- Last Posted Date
- 2007-11-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 24
- Registration Number
- NCT00464880
- Locations
- 🇩🇰
Novartis, Gentofte, Denmark
26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2011-08-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 2059
- Registration Number
- NCT00463567
- Locations
- 🇺🇸
Asthma & Allergy Research Associates, Dallas, Texas, United States
🇺🇸North Shore University Hospital, New Hyde Park, New York, United States
🇺🇸University of North Carolina, Chapel Hill, North Carolina, United States
A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2020-12-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 501
- Registration Number
- NCT00463242
- Locations
- 🇵🇷
Novartis Investigative Site, Hato Rey, Puerto Rico
Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure Infections
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2011-03-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 52
- Registration Number
- NCT00463801
- Locations
- 🇮🇹
Novartis Italy, Saronno, Italy
Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes
Phase 1
Completed
- Conditions
- First Posted Date
- 2007-04-17
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 18
- Registration Number
- NCT00461136
- Locations
- 🇩🇰
Novartis, Gentofte, Denmark
Efficacy of Formoterol vs Ipatropioum Bromide Plus Fenoterol in Children (5-<12 Years) With Acute Bronchial Obstruction
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-04-16
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 60
- Registration Number
- NCT00460577
- Locations
- 🇻🇪
Novartis Investigator site - five sites in Caracas, Caracas, Venezuela
🇻🇪Novartis Investigator Site, Maracaibo, Venezuela
Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-04-12
- Last Posted Date
- 2011-05-06
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1029
- Registration Number
- NCT00459537
- Locations
- 🇹🇷
Novartis Investigative Site, Various Cities, Turkey
Decongestant Effect, Timing of Effect and Impact on Sleep and General Well-Being of Xylometazoline in Subjects With a Common Cold
Phase 3
Completed
- Conditions
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2007-05-03
- Lead Sponsor
- Novartis
- Target Recruit Count
- 60
- Registration Number
- NCT00452270
- Locations
- 🇬🇧
Novartis Investigative Site, Cardiff, Wales, United Kingdom
Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five Years
Phase 4
Completed
- Conditions
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2008-04-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 235
- Registration Number
- NCT00452621
- Locations
- 🇩🇪
Center 11, Eberbach /Neckar, Germany
🇩🇪Center 16, Zirndorf, Germany
🇩🇪Center 1, Weilheim i. OB, Germany
A Comparison of Certoparin and Unfractionated Heparin in the Prevention of Thromboembolic Events in Acutely Ill Medical Patients
- First Posted Date
- 2007-03-23
- Last Posted Date
- 2012-07-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 3254
- Registration Number
- NCT00451412
- Locations
- 🇩🇪
Novartis investigative sites, Nürnberg, Germany
© Copyright 2024. All Rights Reserved by MedPath